Capital Investment Counsel Inc’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$405K Sell
1,610
-43
-3% -$9.25K 0.04% 145
2026
Q1
$360K Buy
1,653
+28
+2% +$6.21K 0.04% 146
2025
Q4
$371K Hold
1,625
0.04% 147
2025
Q3
$376K Sell
1,625
-454
-22% -$92.5K 0.05% 147
2025
Q2
$386K Buy
2,079
+1,025
+97% +$190K 0.05% 137
2025
Q1
$221K Buy
+1,054
New +$205K 0.03% 176
2024
Q4
Sell
-1,329
Closed -$262K 247
2024
Q3
$262K Buy
1,329
+69
+5% +$12.9K 0.04% 161
2024
Q2
$216K Hold
1,260
0.03% 173
2024
Q1
$229K Buy
+1,260
New +$217K 0.04% 170
2022
Q3
Sell
-1,313
Closed -$201K 156
2022
Q2
$201K Buy
1,313
+41
+3% +$6.26K 0.05% 159
2022
Q1
$206K Buy
+1,272
New +$185K 0.04% 168

Other funds holding ABBV

Capital Investment Counsel Inc's ABBV Position: Q2 2026 in Review

Capital Investment Counsel Inc reduced its AbbVie (ABBV) stake by 2.6% in Q2 2026, selling an estimated $9.25K and leaving 1,610 shares worth $405K. The position accounts for 0.04% of the portfolio, ranked #145.

Capital Investment Counsel Inc first reported a position in ABBV in Q1 2022 and has held it in 11 quarters since. 2,639 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Capital Investment Counsel Inc held 1,610 shares of AbbVie worth $405K as of Q2 2026.
  • Capital Investment Counsel Inc sold 43 AbbVie shares in Q2 2026, an estimated $9.25K.
  • AbbVie made up 0.04% of Capital Investment Counsel Inc's portfolio in Q2 2026, its #145 holding.
  • Capital Investment Counsel Inc first reported a position in AbbVie in Q1 2022 and has held it in 11 quarters since.
  • 2,639 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Capital Investment Counsel Inc's 13F filing for Q2 2026, filed 27 Jul 2026.